June 13, 2017 / 12:20 PM / a month ago

BRIEF-Threshold Pharma says first patient dosed in clinical trial of evofosfamide, ipilimumab

1 Min Read

June 13 (Reuters) - Threshold Pharmaceuticals Inc:

* Threshold Pharmaceuticals announces first patient dosed in immunotherapy clinical trial of evofosfamide and ipilimumab

* Threshold Pharmaceuticals Inc - ‍phase 1 clinical trial will evaluate effect of ipilimumab and evofosfamide (TH-302) in advanced solid tumors​

* Threshold Pharmaceuticals Inc - ‍immune-related response evaluation criteria in solid tumors (irrecist) response rate is primary endpoint​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below